Hunan Fangsheng Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603998.SS

Hunan Fangsheng Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2023: USD 36.16 M

Hunan Fangsheng Pharmaceutical Co., Ltd. Receivables is USD 36.16 M for the year ending December 31, 2023, a 30.02% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Hunan Fangsheng Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2022 was USD 27.82 M, a -42.32% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2021 was USD 48.22 M, a 53.28% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2020 was USD 31.46 M, a 24.45% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2019 was USD 25.28 M, a 50.00% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 603998.SS

Hunan Fangsheng Pharmaceutical Co., Ltd.

CEO	Ms. Xiaoli Zhou
IPO Date	Dec. 5, 2014
Location	China
Headquarters	No. 299, Jiayun Road
Employees	1,686
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Hunan Fangsheng Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. It offers medicines in the form of tablets, capsules, and granules for cardiovascular and cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infectives. The company was founded in 2002 and is based in Changsha, China.

Key trends

Past 5 years